Technologies
This technology is a method for enhancing intestinal barrier function for the prevention and treatment of graft-versus-host disease, which is often caused by allogeneic hematopoietic stem cell transplantation (HPSC).
Allogeneic hematopoietic stem cell (HPSC) transplantation, a common therapy for various genetic diseases and cancers, often results in potentially fatal complications, such as graft-versus-host disease (GVHD). It is thought that GVHD arises from perturbations in the intestinal microbiota following allogeneic HPSC transplantation, leading to increased leukocyte activation characteristic of this complication. As such, a treatment that enhances intestinal resilience may prevent the onset of GVHD in transplant patients.
This technology uses analogs of glucagon-like peptide 2 (GLP-2) to bolster intestinal barrier function in hematopoietic stem cell transplant recipients to protect against GVHD. Using a specified dosing schedule that promotes tissue repair, the proposed therapeutic regimen significantly reduces intestinal permeability that contributes to inflammation and GVHD onset. With few off-target effects and a low toxicity profile, this technology may be used in conjunction with existing therapeutic regimens to significantly reduce the incidence of GVHD in HPSC-transplant recipients.
This technology has been validated in mouse models of allogeneic HPSC transplantation.
Patent Pending (US20230364196)
IR CU19098, CU23034, CU18125
Licensing Contact: Jerry Kokoshka